Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Block Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $527.48 (market cap $134.25B), while Block Inc trades at $77.83 (market cap $47.50B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× Block Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals.
| VRTX | XYZ | |
|---|---|---|
Market Cap | $134.25B | $47.50B |
Sector | Health | Technology |
52-Week High | $529.65 | $84.64 |
52-Week Low | $376.62 | $49.04 |
Enterprise Value | $128.37B | $42.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
XYZ trades at $77.78, down 1.52% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.02 versus $0.871, driven by 25% gross profit growth in Cash App and Square. The company raised its 2026 profit outlook, reflecting operational momentum amid strategic AI integration and workforce optimization.
The outlook is positive given raised guidance and expanding profitability, but risks include high P/E valuation and net cash flow volatility. Analyst price targets average $99.47, suggesting 28% upside, supported by institutional accumulation and bullish earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
